329 related articles for article (PubMed ID: 27376328)
1. Tumor Targeting and Drug Delivery by Anthrax Toxin.
Bachran C; Leppla SH
Toxins (Basel); 2016 Jul; 8(7):. PubMed ID: 27376328
[TBL] [Abstract][Full Text] [Related]
2. Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Peters DE; Hoover B; Cloud LG; Liu S; Molinolo AA; Leppla SH; Bugge TH
Toxicol Appl Pharmacol; 2014 Sep; 279(2):220-9. PubMed ID: 24971906
[TBL] [Abstract][Full Text] [Related]
3. Interactions between anthrax toxin receptors and protective antigen.
Scobie HM; Young JA
Curr Opin Microbiol; 2005 Feb; 8(1):106-12. PubMed ID: 15694864
[TBL] [Abstract][Full Text] [Related]
4. Anthrax toxin-mediated delivery of the Pseudomonas exotoxin A enzymatic domain to the cytosol of tumor cells via cleavable ubiquitin fusions.
Bachran C; Morley T; Abdelazim S; Fattah RJ; Liu S; Leppla SH
mBio; 2013 Apr; 4(3):e00201-13. PubMed ID: 23631917
[TBL] [Abstract][Full Text] [Related]
5. Anthrax fusion protein therapy of cancer.
Frankel AE; Powell BL; Duesbery NS; Vande Woude GF; Leppla SH
Curr Protein Pept Sci; 2002 Aug; 3(4):399-407. PubMed ID: 12370003
[TBL] [Abstract][Full Text] [Related]
6. Critical Issues in the Development of Immunotoxins for Anticancer Therapy.
Kim JS; Jun SY; Kim YS
J Pharm Sci; 2020 Jan; 109(1):104-115. PubMed ID: 31669121
[TBL] [Abstract][Full Text] [Related]
7. Anthrax toxin receptor proteins.
Bradley KA; Young JA
Biochem Pharmacol; 2003 Feb; 65(3):309-14. PubMed ID: 12527323
[TBL] [Abstract][Full Text] [Related]
8. Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.
Fischer ES; Campbell WA; Liu S; Ghirlando R; Fattah RJ; Bugge TH; Leppla SH
Protein Sci; 2019 Jun; 28(6):1059-1070. PubMed ID: 30942916
[TBL] [Abstract][Full Text] [Related]
9. Anthrax toxin: structures, functions and tumour targeting.
Liu S; Schubert RL; Bugge TH; Leppla SH
Expert Opin Biol Ther; 2003 Aug; 3(5):843-53. PubMed ID: 12880383
[TBL] [Abstract][Full Text] [Related]
10. Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Liu S; Aaronson H; Mitola DJ; Leppla SH; Bugge TH
Proc Natl Acad Sci U S A; 2003 Jan; 100(2):657-62. PubMed ID: 12525700
[TBL] [Abstract][Full Text] [Related]
11. The Ins and Outs of Anthrax Toxin.
Friebe S; van der Goot FG; Bürgi J
Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26978402
[TBL] [Abstract][Full Text] [Related]
12. Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.
Martin EW; Buzza MS; Driesbaugh KH; Liu S; Fortenberry YM; Leppla SH; Antalis TM
Oncotarget; 2015 Oct; 6(32):33534-53. PubMed ID: 26392335
[TBL] [Abstract][Full Text] [Related]
13. Where and how do anthrax toxins exit endosomes to intoxicate host cells?
Puhar A; Montecucco C
Trends Microbiol; 2007 Nov; 15(11):477-82. PubMed ID: 17983750
[TBL] [Abstract][Full Text] [Related]
14. Peptide Probes Reveal a Hydrophobic Steric Ratchet in the Anthrax Toxin Protective Antigen Translocase.
Colby JM; Krantz BA
J Mol Biol; 2015 Nov; 427(22):3598-3606. PubMed ID: 26363343
[TBL] [Abstract][Full Text] [Related]
15. Anthrax toxin channel: What we know based on over 30 years of research.
Liu W; Nestorovich EM
Biochim Biophys Acta Biomembr; 2021 Nov; 1863(11):183715. PubMed ID: 34332985
[TBL] [Abstract][Full Text] [Related]
16. Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy.
Sherer K; Li Y; Cui X; Eichacker PQ
Am J Respir Crit Care Med; 2007 Feb; 175(3):211-21. PubMed ID: 17095744
[TBL] [Abstract][Full Text] [Related]
17. Development of a receptor-based inhibitory penta-unit-conjugated peptide to enhance anthrax toxin neutralization.
Lee SC; Yoon MY
Int J Biol Macromol; 2020 Nov; 163():327-335. PubMed ID: 32619663
[TBL] [Abstract][Full Text] [Related]
18. Lethal factor of anthrax toxin binds monomeric form of protective antigen.
Chvyrkova I; Zhang XC; Terzyan S
Biochem Biophys Res Commun; 2007 Aug; 360(3):690-5. PubMed ID: 17617379
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of the effect of cell type and cellular differentiation on protective antigen binding to human target cells.
Deshpande A; Hammon RJ; Sanders CK; Graves SW
FEBS Lett; 2006 Jul; 580(17):4172-5. PubMed ID: 16828760
[TBL] [Abstract][Full Text] [Related]
20. A soluble receptor decoy protects rats against anthrax lethal toxin challenge.
Scobie HM; Thomas D; Marlett JM; Destito G; Wigelsworth DJ; Collier RJ; Young JA; Manchester M
J Infect Dis; 2005 Sep; 192(6):1047-51. PubMed ID: 16107958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
